Plasma containingtrazodone or mianserin was extracted.
examined,nortriptyline co-eluteswith the internal standard used inthetrazodone assay,whileflurazepamco-elutes with mianserin. Concentrations oftrazodone in 26 patients ranged from 73 to 1678 p.g/L. For two genatric patients, concentrationswere about2000gIL. For two overdose patients, they
were about 5000 sg/L.The concentration ofmianserin was 27 g/L for a volunteer treated witha single 40-mg oral dose. in Europe, Australia, and New Zealand (1-7). According to recent reviews of the pharmacological properties of TRA (3) and MIA (7) , they do not have anticholinergic side effects and their cardiovascular toxicity is relatively low (6) (7) (8) (9) . However, TRA may cause ventricular ectopy (10). Therapeutic and toxic concentrations in plasma have not been established for TRA and MIA, but even overdoses were reportedly well tolerated (3,
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7, 11).
Ankier et al. (2) developed a liquid-chromatographic (LC) assay for TRA and used it to estimate the pharmacokinetic parameters.
Ether was the extractant, and the internal standard, Figure   1 ), was added only after the extraction. Caccia et al. (12) described two separate gas-chromatographic assays for TRA and an active metabolite of it, 1-(m-chloro)-phenylpiperazine.
Drug Analysis Division, Dept. of Laboratory Medicine, University of Connecticut School of Medicine, Farmington, CT 06032. MIA has been quantified by gas-chromatography or mass-fragmentography (4, 9, 13) and by LC with electrochemical detection (14) . A simple, yet reliable clinical LC assay for MIA is still lacking.
Here we describe simple liquid-chromatographic assays for TRA and MLA that differ from previously reported procedures. The internal standard is added before extraction, and detection is at 214 urn.
Materials and Methods
Materials
Instrumentation. 49442). Isoamyl alcohol, orthophosphoric acid, sodium hydroxide, and potassium dihydrogen phosphate were "BakerAnalyzed" reagent grade (J. T. Baker Chemical Co., Phillipsburg, NJ 08865).
For the precision studies, we prepared the "quality control" samples by adding 40 ML of the stock methanolic solution of TRA or 1 mL of the standard methanolic solution of MIA to two separate 100-mL silanized volumetric flasks. The methanol was evaporated under nitrogen and 100 mL of "drug-free" plasma was then added to each residue, giving final concentrations of 400 gfL for TEA and 100 gfL for
Sample Collection
Blood was sampled from 29 patients who had been treated with TEA for at least three days (5 x 4,2 = 50 h), either just before the next dose (50 to 300 mg, given two or three times daily) or 12 h later to assess "trough" (steady-state) TEA concentrations in plasma. For sampling we used lavendertop Vacutainer Tubes (Becton Dickinson, Rutherford, NJ 07070) containing EDTA but with no tris(2-butoxyethyl) phosphate plasticizer in the rubber stopper. For monitoring MIA, a volunteer ingested 40 mg of MIA; blood was sampled 2 h later.
Procedures
TRA assay is a two-step extraction procedure-organic extraction and evaporation/reconstitution.
To a series of silanized test tubes containing 1 mL of "drug-free" plasma, Inject 100-ML aliquots into the chromatograph, which is operated in the following arrangement: column, Bondapak C18 with BondapakiCorasil guard column; mobile phase, phosphate (50 mmol/L, pH 4.7)/acetonitrile (72/28 by vol); flow rate, 2.5 mL/min; detection wavelength, 214 urn at 0.01 to 0.05A (full scale); injection volume, 100 ML; and temperature, 60#{176}C. Plot peak-height ratios (TRAITRA-IS) vs TRA concentrations.
Estimate the TEA concentrations in the "quality control" samples and patients' samples from this plot.
MIA assay is similar to our previously published procedure (15), except that the amount of internal standard, Cl-1W, is decreased to 200 ng. Figure   2 shows the chromatograms of plasma extracts containing TRA. The respective retention volumes of TEA and TRA-IS were 20 and 40 mL. "Drug-free" plasma chromatogrants ( Figure 2A ) did not show any interference peaks with TEA. Peak-height ratios were linearly correlated with TRA concentrations from 25 to 2000 zg/L (r2 = 0.9994, y = 0.0023x -0.0309). Sensitivity, defined as signal-to-noise ratio of 3, was 5 ng. Table 1 shows the precision and recovery data. The TRA concentration in a plasma sample from a patient receiving 150 mg of TEA daily was 384 g/L ( Figure 2C ). During the past 12 months, we monitored 29 TRA-treated patients receiving 50-to 300-mg daily doses and two overdose patients. Their TEA concentrations may be divided into four groups, as follows: indicative of non-compliance; (b) n = 26, range = 73 to 1678 g/L, and mean = 639 g/L, steady-state (trough) concentrations; (c) n = 2, 1983 and 1938 p.g/L, two geriatric patients receiving 300-mg daily doses; and (d) n = 2 , about 5000 g/L, the overdose patients. The steady-state concentrations did not follow gaussian distribution, but tended to cluster between 100 and 600 g/L. Figure 3 shows the chromatograms of plasma extracts containing MIA. The column retention volume of MIA was 9 mL. The chromatogram of "drug-free" plasma ( Figure 3A ) did not show any interference peak with MIA. Peak-height ratios (MIA/Cl-IMI) were linearly correlated to MIA copcentrations from 25 to 200 gIL (r2 = 0.9995, y = 0.0085x -0.0091). Sensitivity, as defined previously, was 5 ng. Table 1 shows the precision and recovery data. A volunteer's plasma concentration of MIA was 27 gIL ( Figure 3C ). Table 2 shows that nortriptyline interferes with TRA-IS, while flurazepam interferes with MIA.
Results
(a) n = 1, 0 g/L,
Discussion
Both TEA and M1A are new "second-generation" antidepressants, for which therapeutic and toxic ranges are as yet unestablished.
At present, monitoring of TEA and MIA may help to define the "therapeutic range" for a particular patient, to check for noncompliance, to check for possible causes of side effects (important for geriatric patients), and to ascertain the drug elimination in overdose cases. Thus we undertook this study. 
Assay Conditions
The present LC assay for TEA differs from the "highperformance" liquid-chromatographic assay of Ankier et al. (2) and from the gas-chromatographic assay of Caccia et al. (12). TRA-IS was added to the plasma before any extraction step, assuring acceptable precision. We avoided back-extraction of samples, owing to associated poor recoveries (<50%); instead, after evaporating the organic phase, we reconstituted the extracts with dilute acid. A "volatile" interference peak with TEA was eliminated by the evaporation at 40#{176}C.
Analytical recovery was about 80%. In optimizing the chromatographic conditions, we systematically evaluated the relationship of the capacity factors, k', of TEA and TEA-IS at two temperatures (50 #{176}C and 60 #{176}C), and at various percentages of acetonitrile. Under these optimized conditions an interfering peak (tR = 10.5 mm and k' = 7.8) was completely resolved from either TEA or TRA-IS. Given the tR of TEA-IS at 15 mm, the total analysis time is about 16 mm. Preparation and assay of seven standards, two "quality-control" samples, and five patients' samples may be readily completed within 4 h.
During the preliminary precision study, in which we used both aqueous and methanolic standard solutions of TEA, the between-run CVs of the "quality control" samples exceeded 10%, perhaps because of TEA decomposition. A subsequent study of standard solutions of TEA in plasma showed between-run CVs < 10%. Moreover, these solutions, if frozen at -20 #{176}C, are stable for as long as three months.
For monitoring suspected overdose cases involving TRA, the preparation of an additional patient's sample diluted with "drug-free" plasma is necessary. Although nortriptyline co-elutes with TEA-IS, co-administration of nortriptyline and TEA to a patient is unlikely, and this co-elution would not cause an interference problem in the assay. As a precaution for monitoring patients whose medication is being changed from amitriptyline or nortriptyline to TEA, a "wash-out" period of two to three weeks should be allowed before monitoring for TRA.
Patients' Studies
During the past nine months, we used this assay to monitor patients treated with TEA. One group (n = 26)
showed substantial concentrations of TEA in plasma (mean, 
